Botulinum Toxin Type A for Neuroma Pain
WithdrawnPhase 2NCT01374191
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to determine if botulinum toxin type A (Btx-A) is an effective treatment for painful neuromas. The ideal therapy for painful neuromas would be effective, non-addictive, safe, localized, and cost-effective treatment. At the same time, the therapy would also address the complex peripheral and central mechanisms. Btx-A is a potential treatment that addresses each of these requirements while preserving the existing sensation and function. Study Hypothesis: Btx-A injection relieves neuroma pain better than a placebo
Study details
- Official title
- A Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial of Botulinum Toxin Type A for Neuroma Pain
- Conditions
- Neuroma
- Interventions
- Drug: onabotulinum toxin type-A
- Other: placebo
- Drug: 2nd phase - onabotulinum toxin type-A
- Sponsor
- Southern Illinois University
- Start date
- 2015-01
- Primary completion
- 2017-05
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male or female * aged 18-75 years * diagnosed with neuroma pain * able to return/be available for follow-up evaluations * willingness and ability to give informed consent Exclusion Criteria: * positive for HIV/AIDS or otherwise immunocompromised * history of neuromuscular disease * reported allergy to BOTOX® * history or symptoms of any significant medical problem in the last year (i.e., bradycardia, impaired cardiovascular function, liver disease) * symptoms of infection or illness with initial enrollment * pregnant or lactating women * unable or unwilling to maintain abstinence or use contraception for 28 days following all injections * cognitively impaired patients unable to give informed consent
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01374191